NCT06641908RecruitingPhase 1
A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.21 sites in 6 countries52 target enrollmentStarted: November 8, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 52
- Locations
- 21
- Primary Endpoint
- Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)
Study Overview
Brief Summary
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype.
Study details include:
Study Duration per participant: Approximately 4 months
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Escalation A: participants with documented histopathological diagnosis of locally advanced or metastatic STS with unresectable disease that has progressed after at least one prior line of anthracycline-containing systemic therapy for the locally advanced/metastatic setting.
- •Participants with resectable locally advanced or metastatic disease, who had surgery before study entry will be allowed in the trial if there is residual disease after surgery and if the surgery was performed at least 4 weeks before first dose of study intervention.
- •Escalation B: participants with documented histopathological diagnosis of glioblastoma, IDH-wildtype, who have progressed after ONLY one prior line of therapy (including radiotherapy +/- temozolomide, depending on the O^6-methylguanine-DNA methyltransferase [MGMT] status) and relapsing at least 3 months after the end of the radiotherapy treatment.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1
- •Participants with adequate hematologic, hepatic and renal function as defined in protocol
- •Other protocol defined inclusion criteria could apply
Exclusion Criteria
- •Participant has a history of malignancy other than STS or glioblastoma (depending on the escalation/expansion cohort) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, is considered cured with minimal risk of recurrence within 3 years).
- •STS only: Participants with history of brain metastasis, leptomeningeal metastasis, or participants with spinal cord compression
- •Other protocol defined exclusion criteria could apply.
Arms & Interventions
Dose Escalation: M3554 Monotherapy
Experimental
Intervention: M3554 (Drug)
Outcomes
Primary Outcomes
Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)
Time Frame: up to 4 months
Secondary Outcomes
- Change from Baseline in Corrected QT Interval (QTc) Interval(Pre-dose on Day 1 (baseline) up to 24 hours post-dose Day 1, Day 2, Day 5, Day 8 of Cycle 1 and Cycle 3 Day 1 (each Cycle is 21 days))
- Pharmacokinetic (PK) Plasma Concentrations of M3554(Cycle 1 Day 1 to Cycle 3 Day 15 and every second cycle from Cycle 4 (each cycle is of 21 days), assessed up to approximately 4 months)
- Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 as Assessed by Investigator(Time from randomization to planned assessment at 4 months)
- Duration of Response (DoR) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator(Time from randomization to planned assessment at 4 months)
- Progression-free Survival (PFS) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator(Time from randomization to planned assessment at 4 months)
Investigators
Study Sites (21)
Loading locations...
Similar Trials
Terminated
Phase 1
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaMultiple MyelomaNCT06163898Celgene4
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic MalignanciesMyelodysplastic SyndromesNCT02074839Institut de Recherches Internationales Servier291
Completed
Phase 1
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationAcute Myeloid Leukemia (AML)Hematologic MalignanciesMyelodysplastic SyndromeNCT02492737Agios Pharmaceuticals, Inc.46
Terminated
Phase 1
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung CancersLung CancerOvarian CancerNCT06376253Novartis Pharmaceuticals4
Completed
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 MutationChondrosarcomaOther Advanced Solid TumorsGliomaCholangiocarcinomaNCT02073994Institut de Recherches Internationales Servier174